查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1491689

导管相关血流感染市场：按药物类别、给药途径、适应症、分销管道划分 - 全球预测 2024-2030 年

Catheter-related Bloodstream Infections Market by Drug Class (Cefazoline, Ceftazidime, Cloxacillin), Route of Administration (Injectable, Oral), Indication, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

导管相关血流感染市场规模预计2023年为16.4亿美元，预计2024年将达到17.4亿美元，2030年将达到24.6亿美元，复合年增长率为5.88%。

导管相关性血流感染 (CRBSI) 是细菌或真菌经由中心静脉管或导管进入血流时发生的感染疾病，中心静脉管或导管是放置在大静脉中进行治疗的管子。医院和临床环境中接受静脉注射治疗的患者数量不断增加，对旨在降低 CRBSI 发生率的先进导管的需求显着增加。此类感染疾病在全球日益流行，凸显了对确保静脉注射药物安全输送的产品的需求，从而推动了市场成长。然而，严格的药品监管和产品召回是主要企业面临的重大挑战。此外，我们还看到专门从事医疗设备和医院护理解决方案的主要公司之间联盟和合併的重大趋势。这些合作旨在创新和增强导管技术以预防感染，从而扩大分销网络并改善产品供应，从而提高市场覆盖率和渗透率。

主要市场统计
基准年[2023] 16.4亿美元
预测年份 [2024] 17.4亿美元
预测年份 [2030] 24.6亿美元
复合年增长率（%） 5.88%

区域洞察

由于医疗保健系统结构和政策的多样性，美洲地区的消费者需求和购买行为有所不同，尤其是美国和加拿大。美国医疗技术采用率很高，包括先进的 CRBSI 预防技术，如抗菌导管和洛赫西定敷料。已分配大量资金用于 CRBSI 的研究，从而导致持续的临床试验和感染预防的发展。疾病管制与预防美国(CDC) 在製定指引和方案方面也发挥着至关重要的作用。同时，EMEA（欧洲、中东和非洲）地区对 CRBSI 的反应呈现多样化，反映出医疗基础架构层、资金和公共卫生政策的差异。欧盟国家受益于合作医疗标准和通用研究倡议。正在进行的研究重点是 CRBSI 预防的技术和程序方面。欧盟委员会的框架支持成员国之间开展联合研究来解决 HAI。此外，在亚太地区，中国、日本和印度等国家是医疗保健领域的主要参与者，并深受 Theme_KEYWORD (CRBSI) 的影响。由于人口密度高和医疗基础设施不稳定，这些感染疾病在该地区尤其严重。最近关于 CRBSI 预防技术的区域专利强调了导管设计和抗菌应用的改进。对医疗保健改善的投资，包括政府主导的感染控制通讯协定，是稳健的。

FPNV定位矩阵

FPNV 定位矩阵对于评估供应商在导管相关血流感染市场的定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可对导管相关血流感染市场供应商的现况进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外，该分析还提供了对该行业竞争性质的宝贵见解，包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在导管相关血流感染市场中的地位进行全面评估，使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对静脉细菌感染疾病的日益关注以及对有效治疗方法的需求
      • 提高对导管相关血流的认识宣传活动
    • 抑制因素
      • 有关药品核准和产品召回的严格政府法规
    • 机会
      • 首选政府针对细菌感染疾病的措施和政策
      • 持续进行研究和开发活动，以推动药物输送和开发新药的进步
    • 任务
      • 导管相关的血流感染过敏原和与药物相关的严重健康问题
  • 市场区隔分析
    • 药物类别：广泛使用Cefazolin和氯唑西林药物治疗导管引起的细菌感染疾病
    • 适应症：人们对有效管理以及预防和治疗病毒和寄生虫感染疾病的兴趣日益浓厚
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章依药物类别分類的导管相关血流感染市场

  • Cefazolin
  • 头孢他兹健身房
  • 氯唑西林
  • Daptomycin
  • Echinocandins
  • Teicoplanin
  • 万古霉素

第七章导管相关血流感染市场：依给药途径

  • 可注射的
  • 口服

第八章导管相关血流感染市场（按适应症）

  • 细菌感染疾病
  • 霉菌感染疾病
  • 病毒和寄生虫感染疾病

第九章导管相关血流感染市场：依通路分类

  • 医院药房
  • 网路药房
  • 零售药房

第10章美洲导管相关血流感染市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区导管相关血流感染市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲导管相关血流感染市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Citius Pharmaceuticals 宣布完成 Mino-Lok 用于缓解感染导管的 3 期研究的招募
    • BD 与 Bactiguard 合作，增强全球感染预防Foley导管的可及性
    • FDA核准DefenCath 是预防血液透析机病人导管相关血流感染的重要一步。
  • 战略分析和建议

第14章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-5D693B46C67B

[187 Pages Report] The Catheter-related Bloodstream Infections Market size was estimated at USD 1.64 billion in 2023 and expected to reach USD 1.74 billion in 2024, at a CAGR 5.88% to reach USD 2.46 billion by 2030.

Catheter-related bloodstream infections (CRBSIs) refer to infections acquired when bacteria and fungi enter the bloodstream through a central line or catheter, which are tubes placed in large veins for medical treatments. Increased patient admissions in hospitals and clinical settings that utilize intravenous treatments have significantly boosted the demand for advanced catheters designed to reduce the incidence of catheter-related bloodstream infections (CRBSIs). The rising prevalence of these infections globally underscores the need for products that guarantee safer delivery of intravenous medicines, thus propelling market growth. However, strict regulations related to drugs and product recalls are the significant challenge faced by the key companies. Moreover, there is a notable trend of partnerships and amalgamations among significant companies that specialize in medical devices and hospital care solutions. These collaborations aim to innovate and enhance catheter technologies that prevent infections, resulting in expanded distribution networks and improved product offerings, which in turn enhance market reach and penetration.

KEY MARKET STATISTICS
Base Year [2023] USD 1.64 billion
Estimated Year [2024] USD 1.74 billion
Forecast Year [2030] USD 2.46 billion
CAGR (%) 5.88%

Regional Insights

The Americas, particularly the United States and Canada show differing degrees of consumer needs and purchasing behaviors due to diversity in healthcare system structures and policies. The United States has a significant rate of medical technology adoption, which includes advanced CRBSI prevention technologies like antimicrobial catheters and chlorhexidine dressings. Substantial funding is being allocated to research on CRBSIs, which will lead to ongoing clinical trials and developments in infection prevention. The Centers for Disease Control and Prevention (CDC) also plays a pivotal role in setting guidelines and protocols. At the same time, the EMEA region shows varied responses to CRBSIs, reflecting different healthcare infrastructure levels, funding, and public health policies. Countries within the EU benefit from cooperative healthcare standards and shared research initiatives. Ongoing research focuses on the technological and procedural aspects of CRBSI prevention. European Commission frameworks support research collaborations across member states to address HAIs. Moreover, in the Asia Pacific region, countries including China, Japan, and India are key players in the healthcare sector, profoundly impacted by catheter-related bloodstream infections (CRBSIs). These infections are especially critical due to the region's high population densities and varying healthcare infrastructure. Recent regional patents for CRBSI prevention technology emphasize improvements in catheter design and antimicrobial applications. Investments are robust in healthcare improvements, including infection control protocols driven by the government.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Catheter-related Bloodstream Infections Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing concerns about intravenous bacterial infections and the need for effective treatment options
      • Growing number of educational campaigns for awareness of catheter-related bloodstream
    • Market Restraints
      • Strict government regulations related to drug approvals and cases of product recalls
    • Market Opportunities
      • Favorable government initiatives and policies for bacterial infectious diseases
      • Advancements in the drug delivery and ongoing R&D activities for the novel drug development
    • Market Challenges
      • Allergens and significant health concerns associated with catheter-related bloodstream infections medications
  • Market Segmentation Analysis
    • Drug Class: Extensive utililzation of Cefazoline and Cloxacillin medication in the treatment of bacterial infections caused by catheter
    • Indication: Growing focus on the effective management and the prevention and treatment of viral & parasitic infections
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Catheter-related Bloodstream Infections Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Catheter-related Bloodstream Infections Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Citius Pharmaceuticals Announces Completion of Phase 3 Trial Enrollment for Mino-Lok, Aiming to Salvage Infected Catheters

Citius Pharmaceuticals completed patient enrollment for the pivotal Phase 3 clinical trial of Mino-Lok, an antibiotic therapy designed to treat catheter-related bloodstream infections (CRBSIs). This significant milestone marks a crucial step towards providing a potentially life-saving treatment option to salvage infected central venous catheters (CVCs), thereby avoiding the need for their removal and replacement. This therapeutic approach aims to enhance patient outcomes and seeks to reduce healthcare costs and procedural complications associated with the current standard practice of catheter replacement. [Published On: 2024-01-02]

BD Partners with Bactiguard to Enhance Global Access to Infection-Preventing Foley Catheters

Becton Dickinson and Company (BD) has secured an exclusive global licensing partnership, excluding China, with Bactiguard for its innovative Bactiguard-coated Foley catheters. This agreement marks a significant expansion in the distribution of Bactiguard's infection prevention technology, which is integrated into Foley catheters to reduce the risk of catheter-related bloodstream infections. This partnership aims to enhance patient outcomes by broadening the availability of these advanced medical devices, potentially impacting healthcare standards globally. [Published On: 2023-12-14]

FDA Approval of DefenCath Marks a Significant Step in Catheter-Related Bloodstream Infection Prevention for Hemodialysis Patients

CorMedix Inc. received U.S. Food and Drug Administration (FDA) approval for DefenCath, a catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs) in adult hemodialysis patients. This approval underscores the effectiveness of DefenCath in reducing the risks of CRBSIs, a common and serious complication that affects patients with central venous catheters. DefenCath's active ingredient is taurolidine, which is known for its antimicrobial properties and significantly enhances patient safety during hemodialysis. [Published On: 2023-11-15]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Catheter-related Bloodstream Infections Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Catheter-related Bloodstream Infections Market, highlighting leading vendors and their innovative profiles. These include Advacare Pharma, AstraZeneca PLC, Bactiguard AB, Becton, Dickinson and Company, CorMedix Inc, Fresenius Medical Care AG, Glenmark Pharmaceuticals Ltd., IntegraDose Compounding Services, LLC, Johnson & Johnson Services, Inc, JoinHub Pharma, Lupin Ltd., Lyka Hetero Healthcare Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, TauroPhar GmbH, and Xellia Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Catheter-related Bloodstream Infections Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Cefazoline
    • Ceftazidime
    • Cloxacillin
    • Daptomycin
    • Echinocandin
    • Teicoplanin
    • Vancomycin
  • Route of Administration
    • Injectable
    • Oral
  • Indication
    • Bacterial Infections
    • Fungal Infection
    • Viral & Parasitic Infections
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing concerns about intravenous bacterial infections and the need for effective treatment options
      • 5.1.1.2. Growing number of educational campaigns for awareness of catheter-related bloodstream
    • 5.1.2. Restraints
      • 5.1.2.1. Strict government regulations related to drug approvals and cases of product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable government initiatives and policies for bacterial infectious diseases
      • 5.1.3.2. Advancements in the drug delivery and ongoing R&D activities for the novel drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Allergens and significant health concerns associated with catheter-related bloodstream infections medications
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Extensive utililzation of Cefazoline and Cloxacillin medication in the treatment of bacterial infections caused by catheter
    • 5.2.2. Indication: Growing focus on the effective management and the prevention and treatment of viral & parasitic infections
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Catheter-related Bloodstream Infections Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Cefazoline
  • 6.3. Ceftazidime
  • 6.4. Cloxacillin
  • 6.5. Daptomycin
  • 6.6. Echinocandin
  • 6.7. Teicoplanin
  • 6.8. Vancomycin

7. Catheter-related Bloodstream Infections Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Catheter-related Bloodstream Infections Market, by Indication

  • 8.1. Introduction
  • 8.2. Bacterial Infections
  • 8.3. Fungal Infection
  • 8.4. Viral & Parasitic Infections

9. Catheter-related Bloodstream Infections Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Catheter-related Bloodstream Infections Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Catheter-related Bloodstream Infections Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Catheter-related Bloodstream Infections Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Citius Pharmaceuticals Announces Completion of Phase 3 Trial Enrollment for Mino-Lok, Aiming to Salvage Infected Catheters
    • 13.3.2. BD Partners with Bactiguard to Enhance Global Access to Infection-Preventing Foley Catheters
    • 13.3.3. FDA Approval of DefenCath Marks a Significant Step in Catheter-Related Bloodstream Infection Prevention for Hemodialysis Patients
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET RESEARCH PROCESS
  • FIGURE 2. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET DYNAMICS
  • FIGURE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CEFAZOLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CEFAZOLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CEFTAZIDIME, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CEFTAZIDIME, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CLOXACILLIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CLOXACILLIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ECHINOCANDIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ECHINOCANDIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INJECTABLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY FUNGAL INFECTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY FUNGAL INFECTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY VIRAL & PARASITIC INFECTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY VIRAL & PARASITIC INFECTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 78. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 85. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 121. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 129. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 130. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 154. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 162. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 169. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 185. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 186. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 219. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 220. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 227. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 228. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 252. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 267. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 276. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA CATHETER-RELATED BLOODSTREAM INFE